Çelik, EmirSamancı, Nilay SengulKaradağ, MehmetDemirci, Nebi SerkanDemirelli, Fuat Hulusi2024-09-192024-09-1920212602-3164https://doi.org/10.14744/ejmi.2021.21203https://search.trdizin.gov.tr/tr/yayin/detay/485336https://hdl.handle.net/20.500.12483/15525Objectives: No study to clarify which inflammation score could best reflect survival in a cohort of metastatic breastcancer (mBC) patients who received everolimus plus exemestane. Methods: The impact of neutrophil/lymphocyte ratio (NLR), platelet/lymphocyte ratio (PLR), systemic immune-inflammation index (SII), and prognostic nutritional index (PNI) on PFS and OS was evaluated. Results: A total of 80 mBC patients were included. Median PFS was 8.9 months and median overall survival (OS) was31.8 months. We found that there was no significant difference between NLR, PLR, SII, and PNI groups for median PFSand OS. Conclusion: Inflammation-based prognostic scores were not correlated with prognosis in patients with mBC who hadbeen treated with everolimus plus exemestane.eninfo:eu-repo/semantics/openAccessArticle5222523110.14744/ejmi.2021.21203485336